Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

A picture of radiologists looking at a screen showing the restaging of the HNSCC

Study Highlights the Potential of Radiomics in Medical Intervention

A recent study conducted by the Medical University of Innsbruck highlights the potential of radiomics in exploring the impacts of Radiochemotherapy (RCT) on patients with Head and Neck Squamous Cell Carcinoma (HNSCC). This study is the first to explore short-term RCT-induced skeletal muscle alterations after RCT in HNSCC patients applying radiomics, a data-driven approach aiming at extracting and processing quantitative data to analyze image-based information.

With the help of the mint Lesion™ Radiomics module, the research examined radiation-induced changes in the sternocleidomastoideus muscle (SCM) and paravertebral musculature (PVM) post-RCT. Analyzing key radiomic features like volume, mean positivity of pixels, and uniformity the study team was able to confirm the optimal window of 6 to 12 weeks for salvage surgery post-RCT, minimizing the risk of complications due to tissue fibrosis. These findings further showcase how radiomics can enhance medical treatment strategies and indicate a bright path for ongoing research in this area.

Read more about the study

Related Resources

Related Resources

Study - free text reporting vs. mint Lesion in clinical routine

Free text reporting in the tumor response assessment of radiologic imaging data is common in clinical routine, whereas in clinical trials standardized…

University Hospital Ulm: Pilot study shows discriminatory power of MRI-based 3d texture analysis for bone lesions

Distinguishing between enchondroma, a benign tumor, and low-grade chondrosarcoma, which is a low-aggressivity malignancy, is a frequent challenge, as…

4 Questions – 4 Answers // Imaging in Clinical Trials

Mint Medical, Inc. Vice President of Clinical Trials, Kelie Luby Discusses Advances in Imaging Analysis in Clinical Trials and What’s Next for Mint…